CN102174474B - 西地那非单克隆抗体及用于检测西地那非的胶体金层析试纸条 - Google Patents
西地那非单克隆抗体及用于检测西地那非的胶体金层析试纸条 Download PDFInfo
- Publication number
- CN102174474B CN102174474B CN 201110004723 CN201110004723A CN102174474B CN 102174474 B CN102174474 B CN 102174474B CN 201110004723 CN201110004723 CN 201110004723 CN 201110004723 A CN201110004723 A CN 201110004723A CN 102174474 B CN102174474 B CN 102174474B
- Authority
- CN
- China
- Prior art keywords
- virga
- monoclonal antibody
- colloid gold
- detection
- sildenafil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 title claims abstract description 84
- 238000012360 testing method Methods 0.000 title claims abstract description 56
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 title abstract description 26
- 229960003310 sildenafil Drugs 0.000 title abstract description 11
- 238000004587 chromatography analysis Methods 0.000 title abstract description 6
- 238000001514 detection method Methods 0.000 claims abstract description 33
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 30
- 239000000427 antigen Substances 0.000 claims abstract description 25
- 102000036639 antigens Human genes 0.000 claims abstract description 25
- 108091007433 antigens Proteins 0.000 claims abstract description 25
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 8
- 241000405119 Virga Species 0.000 claims description 126
- 239000010931 gold Substances 0.000 claims description 58
- 229910052737 gold Inorganic materials 0.000 claims description 58
- 239000000084 colloidal system Substances 0.000 claims description 48
- 238000002360 preparation method Methods 0.000 claims description 24
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 17
- 229940098773 bovine serum albumin Drugs 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 17
- 238000009739 binding Methods 0.000 claims description 14
- 230000027455 binding Effects 0.000 claims description 13
- 241001494479 Pecora Species 0.000 claims description 8
- 239000002250 absorbent Substances 0.000 claims description 8
- 102000014914 Carrier Proteins Human genes 0.000 claims description 7
- 108010078791 Carrier Proteins Proteins 0.000 claims description 7
- 230000028327 secretion Effects 0.000 claims description 7
- 230000002745 absorbent Effects 0.000 claims description 6
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 claims description 4
- 229920004935 Trevira® Polymers 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 230000000890 antigenic effect Effects 0.000 claims description 2
- 108060003552 hemocyanin Proteins 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 17
- 239000003814 drug Substances 0.000 abstract description 10
- 239000006228 supernatant Substances 0.000 abstract description 9
- 238000007689 inspection Methods 0.000 abstract description 8
- 239000000126 substance Substances 0.000 abstract description 4
- 238000000605 extraction Methods 0.000 abstract description 3
- 239000003550 marker Substances 0.000 abstract description 2
- 238000003908 quality control method Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 60
- 241000699666 Mus <mouse, genus> Species 0.000 description 35
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 33
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 30
- 238000006243 chemical reaction Methods 0.000 description 28
- 239000000523 sample Substances 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000007788 liquid Substances 0.000 description 14
- 206010003445 Ascites Diseases 0.000 description 13
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 229960002381 vardenafil Drugs 0.000 description 12
- 239000000872 buffer Substances 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 238000000502 dialysis Methods 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 238000005507 spraying Methods 0.000 description 6
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000013016 damping Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000012460 protein solution Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000024835 cytogamy Effects 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229910021505 gold(III) hydroxide Inorganic materials 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 229940038773 trisodium citrate Drugs 0.000 description 2
- 229940094720 viagra Drugs 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 1
- 101100491335 Caenorhabditis elegans mat-2 gene Proteins 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 238000003453 ammonium sulfate precipitation method Methods 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000009668 clonal growth Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110004723 CN102174474B (zh) | 2011-01-11 | 2011-01-11 | 西地那非单克隆抗体及用于检测西地那非的胶体金层析试纸条 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110004723 CN102174474B (zh) | 2011-01-11 | 2011-01-11 | 西地那非单克隆抗体及用于检测西地那非的胶体金层析试纸条 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102174474A CN102174474A (zh) | 2011-09-07 |
CN102174474B true CN102174474B (zh) | 2013-01-09 |
Family
ID=44517732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110004723 Active CN102174474B (zh) | 2011-01-11 | 2011-01-11 | 西地那非单克隆抗体及用于检测西地那非的胶体金层析试纸条 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102174474B (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102768232B (zh) * | 2012-06-29 | 2014-05-07 | 南京医科大学 | 一种西地那非分子印记膜电化学传感器的制备方法 |
CN103267842B (zh) * | 2013-05-15 | 2016-03-02 | 郭杰标 | 检测中成药违法添加双氯芬酸的免疫胶体金方法 |
CN104502554B (zh) * | 2014-12-17 | 2017-11-07 | 韶关学院 | 一种他达那非及其类似物的纳米胶体金标记免疫测定方法 |
CN106153954A (zh) * | 2016-08-22 | 2016-11-23 | 广东省药品检验所 | 一种苯妥英钠的快速检测方法 |
CN106124759B (zh) * | 2016-08-22 | 2018-07-27 | 广东省药品检验所 | 一种西地那非胶体金检测试纸 |
CN107300617A (zh) * | 2017-07-17 | 2017-10-27 | 广东志道医药科技有限公司 | Pde‑5抑制剂胶体金免疫层析试纸条及其制备和使用方法 |
CN107189987B (zh) * | 2017-07-17 | 2019-08-30 | 江南大学 | 一株分泌抗西地那非单克隆抗体的杂交瘤细胞株yy及其应用 |
CN108752345A (zh) * | 2018-03-23 | 2018-11-06 | 广东工业大学 | 西地那非半抗原、人工抗原及其制备方法 |
CN108548925A (zh) * | 2018-03-28 | 2018-09-18 | 韶关学院 | 三元体系免疫竞争法检测西地那非类药品的量子点免疫层析检测卡及检测方法 |
CN113105538B (zh) * | 2021-04-21 | 2022-06-28 | 杭州奥泰生物技术股份有限公司 | 一种西酞普兰抗原及西酞普兰胶体金检测试纸 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101021479A (zh) * | 2007-03-20 | 2007-08-22 | 北京市药品检验所 | 一种检测西地那非及其衍生物的方法 |
CN101914155A (zh) * | 2010-08-09 | 2010-12-15 | 江苏省南通药品检验所 | 西地那非及其衍生物的人工合成抗原的工艺 |
-
2011
- 2011-01-11 CN CN 201110004723 patent/CN102174474B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101021479A (zh) * | 2007-03-20 | 2007-08-22 | 北京市药品检验所 | 一种检测西地那非及其衍生物的方法 |
CN101914155A (zh) * | 2010-08-09 | 2010-12-15 | 江苏省南通药品检验所 | 西地那非及其衍生物的人工合成抗原的工艺 |
Non-Patent Citations (2)
Title |
---|
W. Weinmann等.Post-mortem detection and identification of sildenafil (Viagra) and its metabolites by LC/MS and LC/MS/MS.《International Journal of Legal Medicine》.2000,第114卷252–258页. * |
王尧尧.功能食品中西地那非酶联免疫检测方法的研究.《中国优秀硕士学位论文全文数据库工程科技I辑》.2010,(第6期),论文正文. * |
Also Published As
Publication number | Publication date |
---|---|
CN102174474A (zh) | 2011-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102174474B (zh) | 西地那非单克隆抗体及用于检测西地那非的胶体金层析试纸条 | |
CN102161662B (zh) | 西地那非及其衍生物的人工合成抗原及其制备方法和应用 | |
CN101962358B (zh) | 环丙沙星半抗原、人工抗原和抗体及其制备方法和应用 | |
CN104356237A (zh) | 一种多效唑单克隆抗体的制备方法 | |
CN104849467A (zh) | 检测盐酸克仑特罗残留的荧光微球免疫层析试纸条及其制备方法和应用 | |
CN103820394A (zh) | 抗吗啡单克隆抗体、产生该抗体的细胞株、吗啡检测试剂盒及其制作方法 | |
CN104459144B (zh) | 一种猪伪狂犬病毒强毒株和疫苗毒株鉴别检测试纸 | |
CN101863981A (zh) | 一种抗双酚a单克隆抗体的制备方法 | |
CN102618502A (zh) | 分泌抗喹诺酮类药物单抗杂交瘤细胞株及其单抗应用 | |
CN105044367A (zh) | 检测牛奶中地塞米松残留的胶体金免疫层析试纸条 | |
CN104007255B (zh) | 一种黄曲霉素b1快速检测试纸条及其制备方法与应用 | |
CN105044365A (zh) | 检测恩诺沙星残留的时间分辨荧光免疫分析试纸的制备方法 | |
CN103333864B (zh) | 抗弓形虫mic3蛋白单克隆抗体及其应用 | |
CN101597334A (zh) | 蓝舌病病毒单克隆抗体及制备方法和应用 | |
CN101429250A (zh) | 霉菌毒素青霉酸单克隆抗体及其制备方法 | |
CN104762267A (zh) | 杂交瘤细胞afb1-2a4及其产生的黄曲霉毒素b1单克隆抗体 | |
CN107988168A (zh) | 抗可卡因单克隆抗体、分泌该抗体的细胞株及制备方法 | |
CN102766212A (zh) | 用于检测氟喹诺酮类药物残留的单克隆抗体及酶联免疫方法与试剂盒 | |
CN102336831A (zh) | 一种抗西地那非的特异性抗体 | |
CN108998424A (zh) | 一株马兜铃酸a单克隆抗体杂交瘤细胞株及其应用 | |
CN105646536A (zh) | 一种头孢噻呋半抗原及其胶体金检测装置及其制备方法 | |
CN103364546B (zh) | 一种检测呋喃唑酮代谢物的试剂盒及方法 | |
CN105628923B (zh) | 一种半定量免疫胶体金试纸条及其应用 | |
CN101962359B (zh) | 恩诺沙星半抗原、人工抗原和抗体及其制备方法和应用 | |
CN101393218A (zh) | 一种单克隆抗体的制备及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: 226000 Jiangsu city of Nantong Province, Nantong economic and Technological Development Zone, Road No. 1692 No. 15 building block A Patentee after: NANTONG EGENS BIOTECHNOLOGY CO., LTD. Address before: 226000 Jiangsu Province, Nantong City Lake Economic and Technological Development Zone, Road No. 1692 No. 15 building block A Patentee before: Nantong Egens Biotechnology Co., Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Sildenafil monoclonal antibody and colloidal gold chromatography test strip used for detecting sildenafil Effective date of registration: 20190109 Granted publication date: 20130109 Pledgee: Bank of China, Limited by Share Ltd, Nantong branch Pledgor: NANTONG EGENS BIOTECHNOLOGY CO., LTD. Registration number: 2019320000025 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200228 Granted publication date: 20130109 Pledgee: Bank of China, Limited by Share Ltd, Nantong branch Pledgor: NANTONG EGENS BIOTECHNOLOGY CO., LTD. Registration number: 2019320000025 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Sildenafil monoclonal antibody and colloidal gold chromatography test strip used for detecting sildenafil Effective date of registration: 20200316 Granted publication date: 20130109 Pledgee: Bank of China, Limited by Share Ltd, Nantong branch Pledgor: NANTONG EGENS BIOTECHNOLOGY Co.,Ltd. Registration number: Y2020980000726 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20201224 Granted publication date: 20130109 Pledgee: Bank of China Limited by Share Ltd. Nantong branch Pledgor: NANTONG EGENS BIOTECHNOLOGY Co.,Ltd. Registration number: Y2020980000726 |